Advancing Type 1 Diabetes Care: Stem Cell-Derived Islet Therapy with Zimislecel
Highlight
• Zimislecel is an innovative stem cell-derived, fully differentiated islet cell therapy for type 1 diabetes that aims to restore physiologic insulin production.
• A phase 1-2 clinical trial demonstrated successful engraftment, islet function evidenced by C-peptide production, insulin independence in 83% of participants, and freedom from severe hypoglycemic events.
• Glucocorticoid-free immunosuppression was used to reduce adverse effects, with neutropenia as the most common serious adverse event.
• Despite a small sample size and short follow-up, these outcomes recommend further research into zimislecel’s therapeutic potential.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.